Moderna, Inc. $MRNA Shares Sold by Himension Capital Singapore PTE. LTD.

Himension Capital Singapore PTE. LTD. reduced its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 38.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 35,338 shares of the company’s stock after selling 22,390 shares during the quarter. Himension Capital Singapore PTE. LTD.’s holdings in Moderna were worth $1,795,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. MUFG Securities EMEA plc bought a new stake in shares of Moderna in the second quarter worth $28,000. Flagship Harbor Advisors LLC bought a new position in Moderna during the 4th quarter valued at $31,000. Canton Hathaway LLC bought a new position in Moderna during the 1st quarter valued at $31,000. Cromwell Holdings LLC grew its holdings in Moderna by 39.7% during the 4th quarter. Cromwell Holdings LLC now owns 1,200 shares of the company’s stock worth $35,000 after acquiring an additional 341 shares in the last quarter. Finally, EverSource Wealth Advisors LLC grew its holdings in Moderna by 148.3% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,341 shares of the company’s stock worth $37,000 after acquiring an additional 801 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Insider Activity

In related news, insider Shannon Thyme Klinger sold 3,471 shares of Moderna stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $50.00, for a total value of $173,550.00. Following the sale, the insider directly owned 67,468 shares in the company, valued at $3,373,400. This trade represents a 4.89% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Abbas Hussain sold 5,682 shares of Moderna stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $46.63, for a total transaction of $264,951.66. Following the completion of the sale, the director owned 12,066 shares in the company, valued at approximately $562,637.58. This represents a 32.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 125,088 shares of company stock worth $6,193,713 in the last 90 days. 10.80% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. The Goldman Sachs Group boosted their target price on shares of Moderna from $49.00 to $67.00 and gave the stock a “neutral” rating in a research report on Tuesday. Morgan Stanley increased their price target on shares of Moderna from $33.00 to $39.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 8th. UBS Group reiterated a “neutral” rating on shares of Moderna in a research note on Tuesday, May 26th. Royal Bank Of Canada boosted their price objective on Moderna from $38.00 to $45.00 and gave the company a “sector perform” rating in a report on Tuesday, July 7th. Finally, Bank of America upped their price objective on Moderna from $34.00 to $38.00 and gave the company an “underperform” rating in a research note on Tuesday, July 7th. Two investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and five have given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Reduce” and a consensus target price of $40.00.

Moderna Trading Up 0.3%

NASDAQ:MRNA opened at $59.66 on Wednesday. Moderna, Inc. has a 12-month low of $22.28 and a 12-month high of $85.60. The firm has a market capitalization of $23.67 billion, a P/E ratio of -7.32 and a beta of 0.94. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.41 and a quick ratio of 2.35. The business has a 50 day simple moving average of $58.13 and a 200 day simple moving average of $51.36.

Moderna (NASDAQ:MRNA) last issued its earnings results on Friday, May 1st. The company reported ($3.40) earnings per share for the quarter, missing the consensus estimate of ($3.02) by ($0.38). The company had revenue of $389.00 million during the quarter, compared to analyst estimates of $236.37 million. Moderna had a negative return on equity of 26.64% and a negative net margin of 143.55%.Moderna’s quarterly revenue was up 260.2% on a year-over-year basis. During the same period in the prior year, the business earned ($2.52) earnings per share. Equities research analysts predict that Moderna, Inc. will post -6.41 EPS for the current year.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.